Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival

Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma

(2021) Lenka Besse et al.   CANCER RESEARCH

Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma

(2020) Dominika Fassmannová et al.   Cancers

DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1

(2020) A. Barbara Dirac-Svejstrup et al.   MOLECULAR CELL

Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis

(2019) Matthew Ho Zhi Guang et al.   Cancers

Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma

(2018) Christoph Driessen et al.   BLOOD

Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

(2017) Matthew Ho Zhi Guang et al.   LEUKEMIA & LYMPHOMA

Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity

(2017) Frederick M. Tomlin et al.   ACS Central Science

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

(2016) G P Soriano et al.   LEUKEMIA

Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1

(2016) Nicolas J Lehrbach et al.   eLife

The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction

(2016) Shun Koizumi et al.   eLife

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

(2016) Xin Wang et al.   Scientific Reports

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

(2015) S Atrash et al.   Blood Cancer Journal

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back

(2014) Giada Bianchi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area

(2014) Giada Bianchi et al.   JOURNAL OF CLINICAL ONCOLOGY

p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition

(2014) Senthil K Radhakrishnan et al.   eLife

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Inhibition of HSP90 molecular chaperones: moving into the clinic

(2013) Rocio Garcia-Carbonero et al.   LANCET ONCOLOGY

Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib

(2013) Tamer B. Shabaneh et al.   PLoS One

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Specific SKN-1/Nrf Stress Responses to Perturbations in Translation Elongation and Proteasome Activity

(2011) Xuan Li et al.   PLoS Genetics

Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells

(2010) Senthil K. Radhakrishnan et al.   MOLECULAR CELL

Proteasomal Degradation Is Transcriptionally Controlled by TCF11 via an ERAD-Dependent Feedback Loop

(2010) Janos Steffen et al.   MOLECULAR CELL

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA